Batch 001 - Live Allocation

3/100 SoldQ4 launch pricing · ends 31 Dec

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

ANXIOLYTIC PEPTIDELimited EvidencePopular

Selank

Tuftsin Analog · 10mg

Status

Limited Evidence

Route

Intranasal / SubQ

Half-life

~2-10 minutes plasma

Class

Tuftsin analog

MechanismGABAergic Modulation

Cohort88 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability is a question for your own doctor. See Informed Consent & Disclaimer.

V-Series Member

$38.48 USD/vial

À-la-carte: $40.50 USD/vial · Save 5%

Q4 launch pricing until 31 Dec · regular $45 USD/vial from 1 Jan

Vials per allocation

Member total (1×)$38.48

À-la-carte total$40.50

Flat per-vial pricing. International shipping $35, free on orders of $250 or more.

What this is

Synthetic heptapeptide. Modulates the HPA axis and GABAergic system - anxiolytic effect without sedation or dependence risk.

Tuftsin Analog · 10mg per vial · lot-tested.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Lot-Tested

Every lot, independent lab

Report and verification code per lot

Used inV-Series

V-02

Focus - Memory & Mental Clarity

Selank · Anxiolytic Peptide

◆ Certificate of Analysis · Selank

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot testing in progress. The independent lab report for this Selank lot will be published here, with its verification code, as soon as it is back.

◉

Clinical Overview

Selank

Selank is a 7-amino-acid synthetic peptide derived from the immunomodulatory peptide tuftsin. Approved in Russia for anxiety disorders.

Demonstrates anxiolytic activity without sedation, dependence, or cognitive impairment.

✦

GABAergic Modulation

Modulates GABA and serotonin systems; anxiolytic in Russian use.

◈

HPA-Axis Effects

Influences stress-axis activity and enkephalin levels.

❖

Evidence Status

Limited Western RCT evidence; not independently replicated at scale.

◈

Mechanism

How It Works

Modulates GABAergic and serotonergic systems. Increases enkephalin levels and modulates HPA axis activity.

Anti-inflammatory and immunomodulatory effects also documented.

✚

Patient Bloodwork Guide

Bloodwork for Cognitive & Neuro Protocols

Nootropic / neuro - Semax, Selank, DSIP, Oxytocin, PT-141, Kisspeptin

These protocols target cognition, mood, stress regulation, and sleep. Their effects are mostly subjective and behavioral, so monitoring leans on functional and stress-axis markers more than a classic blood panel - the aim is to confirm benefit without disrupting your stress hormones or sleep architecture.

Incremental approach. These are low-dose, often short-course or as-needed protocols. Vivre tracks how you actually feel and function alongside a light marker panel, rather than chasing numbers - the subjective response is the primary signal here.

Stress axis & recovery

Cortisol rhythm (AM/PM)Confirms the protocol is calming the stress axis, not over-stimulating it. The key safety/efficacy marker for this group.

HRV (heart-rate variability)A non-blood measure of nervous-system balance and recovery - rises as stress regulation improves.

Brain & vascular health

HomocysteineElevated levels are linked to cognitive risk; a useful baseline to optimize.

BDNFA marker tied to neuroplasticity - context for neuro-supportive protocols (where testing is available).

Routine safety

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

BaselineCortisol rhythm, HRV, homocysteine, plus how you rate mood/focus/sleep.

Month 1HRV and a subjective check-in - is it helping, any over-stimulation?

Month 3Repeat cortisol rhythm and HRV to confirm a sustained, healthy direction.

Educational only - not medical advice or a dosing instruction. Your own doctor orders tests, interprets results and decides what is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Synthetic tuftsin analogue heptapeptide
Studied mechanism	Anxiolytic/immunomodulatory; GABA/monoamine-related effects in regional literature
Human pharmacokinetics	Short peptide half-life; intranasal use studied
Evidence base	Moderate within regional literature; limited Western controlled trials
Form	Lyophilized powder / intranasal, under clinical protocol
Regulatory status	Not an approved therapy in most markets; research use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Evidence base partly regional, limited Western replication. Educational only.

Clinical Literature

Peer-Reviewed References

Anxiolytic and nootropic effects of Tuftsin analogue Selank

Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB · 2003 · Eksperimental'naia i Klinicheskaia Farmakologiia 2003;66(5):3–6

▾

Findings

Original Russian publication describing Selank as a synthetic tuftsin analogue developed at the Russian Academy of Sciences. Preclinical anxiolytic activity and reported nootropic effects in rodent models. Important methodology notes: publication is in Russian; controlled trials in Western peer-reviewed literature are not available. Selank is registered in Russia for generalised anxiety disorder but not approved in the US, EU, or Asia-Pacific markets.

View on publisher ↗

A Brief Review of Selank: A Russian-Developed Anxiolytic Peptide

Various (review-format coverage) · 2017 · Multiple review and case-report sources

▾

Findings

Subsequent reviews summarise Selank's proposed mechanism (modulation of GABAergic and serotonergic systems, interferon-gamma stabilisation) and a small set of Russian clinical reports in generalised anxiety. The evidence base is predominantly Russian-language, with limited independent Western replication. No major-journal RCT for anxiety, cognition, or any other endpoint has been published in Western peer-reviewed literature.

View on publisher ↗

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P · 2016 · Frontiers in Pharmacology 2016;7:31

▾

Findings

Preclinical real-time PCR transcriptomic study in rats. Selank administration modulated expression of multiple genes involved in GABAergic neurotransmission - including GABA-A receptor subunits, GAT-1/GAT-3 transporters, and ion-channel-related genes - within hours of dosing. Establishes a molecular basis for Selank's reported anxiolytic effect via GABAergic modulation rather than direct receptor agonism. Findings are preclinical (rat brain tissue), not human outcomes - but the study is published in a Western-indexed peer-reviewed journal, which strengthens the mechanistic evidence relative to the predominantly Russian-language clinical literature.

View on publisher ↗

Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M · 2017 · Behavioural Neurology 2017;5091027

▾

Findings

Preclinical rat study using the unpredictable chronic mild stress (UCMS) model - a validated paradigm for stress-induced anxiety and depressive behaviours. Co-administration of Selank with diazepam reduced anxiety indicators back toward baseline more effectively than either compound alone, suggesting a non-overlapping mechanism complementary to benzodiazepine GABA-A potentiation. Important framing: preclinical model only. Combination is not approved or studied in humans. The interest of the study for Vivre is the mechanistic hypothesis it supports - that Selank acts as an allosteric/transcriptomic modulator rather than a direct benzodiazepine-like agonist.

View on publisher ↗

Selank is a real compound with a Russian clinical-use history for generalised anxiety disorder. The mechanistic evidence base is stronger than the human-outcome evidence base: Frontiers in Pharmacology 2016 (Volkova) documents GABAergic transcriptomic effects in rats in a Western-indexed peer-reviewed journal, and Behavioural Neurology 2017 (Filatova) documents complementary stress-modulation in rat UCMS models. However, no major-journal Western RCT for human anxiety, cognition, or any other endpoint has been published; the Russian clinical reports are not independently replicated. Selank is not approved in the US, EU, or Asia-Pacific markets. Vivre presents this evidence class honestly - same discipline as Semax and Epithalon. The limited human evidence base is stated here.

◇

Clinical Applications

Indications

Generalized anxiety
Stress-related cognitive impairment
Component of cognitive optimization protocols
Anxiolytic when sedating medications are unsuitable

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~2-10 minutes plasma (parent peptide; Russian Academy of Sciences PK data). Behavioural and biochemical effects last orders of magnitude longer through downstream gene-expression cascades (BDNF, cytokine modulation) and the active metabolite Tuftsin-like fragment.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Approved in Russia. Limited Western clinical literature.

Dosing protocols, administration frequency, and titration schedules are not published on these public pages.

▣

Featured In

V-Series Protocols Including Selank

◎

Commonly Paired

Compounds Often Paired With Selank

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions.

Nootropic Peptide

Semax

ACTH Analog · 10mg

◆ cognitive pair

Selank's anxiolytic mechanism complements Semax's neuroplastic signal - central to Vivre's V-02 cognitive-resilience protocol.

View Semax detail →

Metabolic Coenzyme

NAD+

High-Dose IV · 500mg

◆ energy substrate

NAD+ supports the underlying mitochondrial capacity needed for Selank's HPA-axis effects to translate into measurable resilience. Also part of V-02.

View NAD+ detail →

FOR CUSTOMERS

Mixing guide and dosage calculator

Unlocks once you order Selank: step-by-step mixing with illustrations, storage, and a calculator that converts any dose to syringe units at your vial strength.

READY TO PROCEED

Start with the Biological Audit

Selank is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$38.48 USD/vial

Selank · Member rate